Qin Cheng-Dong, Ma De-Ning, Ren Zheng-Gang, Zhu Xiao-Dong, Wang Cheng-Hao, Wang Ying-Cong, Ye Bo-Gen, Cao Man-Qing, Gao Dong-Mei, Tang Zhao-You
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Chinese Ministry of Education, Shanghai 200032, P.R. China.
Department of Liver Surgery, Fudan University Shanghai Cancer Center, Cancer Hospital, Shanghai 200032, P.R. China.
Oncol Rep. 2017 Mar;37(3):1725-1735. doi: 10.3892/or.2017.5389. Epub 2017 Jan 19.
Our previous studies demonstrated that traditional Chinese herbal medicine 'Songyou Yin' inhibited the growth and invasion of hepatocellular carcinoma (HCC) cells, and altered epithelial‑mesenchymal transition (EMT) markers in oxaliplatin‑treated HCC tissues and cell lines. In the present study, we aimed to explore whether astragaloside IV (AS-IV), a component of 'Songyou Yin', can affect the growth and invasion of HCC cells and the underlying mechanism involved. Human HCC cell lines Huh7 and MHCC97-H, with low and high metastatic potential, respectively, were treated with increasing doses of AS-IV. The Cell Counting Kit-8 (CCK-8), plate clone formation, Transwell, wound healing and immunofluorescence assays were used to investigate the effects of AS-IV on HCC cell proliferation, migration and invasion. The protein expression levels were analyzed by western blotting and immunofluorescence assay. The CCK-8 and plate clone formation assays showed that AS-IV had little effect on the proliferation of HCC cells in vitro. However, the Transwell and wound healing assays demonstrated that AS-IV inhibited the migration and invasion of HCC cells in a dose-dependent manner and the morphology of HCC cells was altered from spindle into oval shaped in the AS-IV pretreated groups. The upregulation of E-cadherin and downregulation of N-cadherin, vimentin, α-SMA and Slug were also observed in the AS-IV pretreated groups. Additionally, AS-IV treatment resulted in a profound decrease in the phosphorylated forms of Akt and GSK-3β, which in turn inhibited the expression of β-catenin. Thus, we conclude that AS-IV attenuates the invasive and migratory abilities of HCC cells through the inhibition of EMT by targeting the Akt/GSK-3β/β-catenin pathway.
我们之前的研究表明,传统中药“松友饮”可抑制肝癌(HCC)细胞的生长和侵袭,并改变奥沙利铂处理的肝癌组织及细胞系中的上皮-间质转化(EMT)标志物。在本研究中,我们旨在探究“松友饮”的成分黄芪甲苷(AS-IV)是否会影响肝癌细胞的生长和侵袭及其潜在机制。分别用递增剂量的AS-IV处理具有低转移潜能和高转移潜能的人肝癌细胞系Huh7和MHCC97-H。采用细胞计数试剂盒-8(CCK-8)、平板克隆形成、Transwell、伤口愈合及免疫荧光试验,研究AS-IV对肝癌细胞增殖、迁移和侵袭的影响。通过蛋白质印迹法和免疫荧光试验分析蛋白表达水平。CCK-8和平板克隆形成试验表明,AS-IV对体外肝癌细胞的增殖影响较小。然而,Transwell试验和伤口愈合试验表明,AS-IV以剂量依赖的方式抑制肝癌细胞的迁移和侵袭,且在AS-IV预处理组中肝癌细胞的形态从梭形变为椭圆形。在AS-IV预处理组中还观察到E-钙黏蛋白上调,N-钙黏蛋白、波形蛋白、α-平滑肌肌动蛋白(α-SMA)和锌指蛋白Slug下调。此外,AS-IV处理导致Akt和糖原合成酶激酶-3β(GSK-3β)的磷酸化形式显著减少,进而抑制β-连环蛋白的表达。因此,我们得出结论,AS-IV通过靶向Akt/GSK-3β/β-连环蛋白信号通路抑制EMT,从而减弱肝癌细胞的侵袭和迁移能力。